Introduction
Macrophage colony stimulating factor (M-CSF, also known as CSF-1) binds to the CSF-1 receptor (CSF-1R), the product of the c-fms proto-oncogene, which results in receptor dimerization and activation of an intrinsic tyrosine kinase activity (Woolford et al., 1985; Sherr et al., 1985; Ullrich and Schlessinger, 1990) . As initially characterized in cells of the monocytemacrophage lineage, activation of this receptor by its cognate ligand is required for macrophage proliferation, dierentiation and survival (Stanley et al., 1983) . CSF-1Rs are also expressed by trophoblasts of the developing placenta, and play an essential role in regulating placental implantation and development (Pollard et al., , 1991 . Recently, we and others have reported the expression of signi®cant levels of CSF-1R by the malignant epithelial cells of breast, ovary, lung and other carcinomas and clinically, such expression of CSF-1R by neoplastic cells correlates with high histologic grade, advanced stage and poor prognosis in ovarian, endometrial and breast carcinomas (Kacinski et al., 1988 (Kacinski et al., , 1990a (Kacinski et al., , 1991 Tang et al., 1992; Scholl et al., 1994) . In addition, in vitro studies have demonstrated that activation of CSF-1R by CSF-1 in breast and ovarian carcinoma cell lines stimulates their ability to invade basement membrane analogues by a urokinase-dependent mechanism Filderman et al., 1992; Chambers et al., 1995; Sapi et al., 1996) . As an autocrine system, the potential of co-expression of CSF-1 and CSF-1R in breast tumors has been highlighted by recent studies ®nding that expression of both CSF-1R and CSF-1 is observed in invasive, but not preinvasive tumors (Tang et al., 1992; Scholl et al., 1994) .
Activation of CSF-1R results in receptor autophosphorylation on several intracellular tyrosine residues (Ullrich and Schlessinger, 1990; Rohrschneider, 1994) . In addition to activation of CSF-1R, CSF-1 stimulation has been shown to modulate the phosphorylation state and/or activity of other signal transduction proteins, some of which are known or believed to associate with CSF-1R at recognition sequences containing a phosphorylated tyrosine. These include the adaptor protein, Grb2, which binds to phosphotyrosine 699 (van der Geer and Hunter, 1993) , p120rasGAP and src-family kinases, both of which appear to require a phosphorylated tyrosine 809 residue for association with CSF-1R (Courtneidge et al., 1993; Trouliaris et al., 1995) , the SHC proteins, a p150 hematopoietic-speci®c inositol phosphatase (Lioubin et al., 1994 (Lioubin et al., , 1996 and phosphatidyl inositol 3' kinase (PI3K) (Varticovski et al., 1989; Reedijk et al., 1990 Reedijk et al., , 1992 . Association of these eector proteins with the receptor most often occurs via their src homology 2 (SH2) domains and phosphotyrosine binding (PTB) domains, which bind speci®c phosphotyrosine containing sequences in activated receptors (Fantl et al., 1992; Songyang et al., 1993; Kavanaugh and Williams, 1994; Alonso et al., 1995) .
Although none of the four major phosphorylated tyrosines of CSF-1R appear to be essential for ligand dependent proliferation, phosphorylation of tyrosine 807 (homologue of human 809) in the kinase catalytic domain (Ohtsuka et al., 1990; Tapley et al., 1990 ; van der Geer and Hunter, 1993) was shown to be essential for the dierentiation of a myeloid precursor cell line (Bourette et al., 1995) and the morphologic alterations generally observed in transformed cells (Trouliaris et al., 1995) . The other three major CSF-1R autophosphorylation sites are located in the unique kinase insert (KI) domain at tyrosines 699, 708 and 723 (homologues of mouse 697, 706 and 721) (Tapley et al., 1990; van der Geer and Hunter, 1990; Reedijk et al., 1992) . The internal tyrosine kinase domain of CSF-1R, like other members of its subclass, which includes PDGF-R (platelet-derived growth factor) and KIT, contains a KI sequence of 70 amino acids which separates the ATP-binding and catalytic regions (Yarden et al., 1986) . This insert sequence is not conserved within the subclass, is not required for protein tyrosine kinase (PTK) activity and is not found in other classes of PTKs (Yarden et al., 1986; Taylor et al., 1989) . While deletion of the KI or point mutations of the individual tyrosines to phenylalanine did not inhibit mitogenesis in ®broblasts, the transforming ability of such mutant CSF-1Rs was markedly impaired (Reedijk et al., 1990) . Studies of deletion mutants (Reedijk et al., 1990) and mutants in which Phe is substituted for Tyr (Reedijk et al., 1992) revealed that tyrosine 723 is the binding site for PI3K which is activated after CSF-1 stimulation of CSF-1R (Varticovski et al., 1989) . PI3K in turn phosphorylates various phosphatidylinositols which may be important modulators of cell proliferation (Cantley et al., 1991; Rameh et al., 1995; de Camilli et al., 1996) . Employing a model system of mammary epithelial cells transformed to express CSF-1R we have also recently reported that tyrosine 721 is necessary for in vitro anchorage-independent growth and the in vivo ability to metastasize when injected into mice (Sapi et al., 1996) .
The availability of antibodies which recognize phosphotyrosines in general has provided the opportunity to analyse phosphorylation of many proteins including receptor tyrosine kinases and their substrates (Ross et al., 1981; Wang, 1988; Comoglio et al., 1990) . The more recent discovery that it is also feasible to raise antibodies to speci®c phosphotyrosines such that they recognize speci®c peptides or proteins only when they are tyrosine phosphorylated (Bangalore et al., 1992) has created a powerful new tool not only for studies of signal transduction, but also for immunohistochemical analyses of proteins phosphorylated in tissue sections. We report here the preparation of an anity puri®ed, polyclonal antiserum raised against a speci®c phosphorylated CSF-1R peptide containing one of four major autophosphorylated tyrosines, amino acid 723. We have applied this antibody preparation (aPY723) to immunohistochemical studies of clinical breast tumor specimens and demonstrate its ability to identify a subset of the CSF-1R positive cases where the receptor appears to be activated in vivo.
Results

CSF-1R phosphopeptide epitope and speci®c antiserum
In order to prepare an immunological reagent capable of discriminating the activated, tyrosine phosphorylated form of CSF-1R from its inactive, unphosphorylated precursor, we chose one of the major autophosphorylation sites in human CSF-1R, tyrosine 723, as a speci®c target epitope. We commissioned the chemical synthesis of a phosphopeptide identical to amino acids 716 to 730 of the human CSF-1R sequence in which a phosphotyrosine was incorporated at position 723 in place of tyrosine. The sequence of the peptide, SSQGVDTpYVEMRPVS, is 100% homologous to the comparable murine sequence (amino acids 714 ± 728). Following previously published protocols (Bangalore et al., 1992) this phosphopeptide (PYpep723) was coupled to bovine serum albumin, mixed with Freund's adjuvant and injected into rabbits.
The resulting phosphopeptide antiserum was puri®ed by anity chromatography as described in Materials and methods. The eluate from the ®nal phosphopeptideanity column was designated aPY723 and assayed for reactivity against immunoblots of whole cell lysates from pZen cells which expresss high levels of murine CSF-1R ( Figure 1a ) and the murine macrophage line BAC1.2F5 (Figure 1b ). Prior to lysate preparation, pZen cells were brie¯y stimulated with 250 ng/ml rhCSF-1 (recombinant human macrophage colony stimulating factor). Immunoblotting with a commercial anti-CSF-1R antibody, which recognizes CSF-1R regardless of its phosphorylation state, shows the presence of both the mature, glycosylated (p165) and immature, mannose-rich (p140) forms of CSF-1R in lysates from both stimulated and Figure 1 Immunoblot analysis with aPY723. Whole cell lysates were subjected to PAGE and electroblotted as described in Materials and methods. Lysates from cells that had been exposed to 250 ng/ml rhCSF-1 for 2. unstimulated pZen cells (Figure 1a , lanes 1 and 2) and BAC1.2F5 cells (Figure 1b, lanes 1 and 2) . Immunoblot analysis of a duplicate set of pZen samples with the commonly used anti-phosphotyrosine antibody 4G10 ( Figure 1a , lanes 3 and 4) shows the phosphorylation on tyrosine of several proteins, including a band corresponding to the mature p165 form of CSF-1R, in response to CSF-1 stimulation but no bands corresponding to CSF-1R in the unstimulated pZen cells. Blotting additional lanes from the same lysates with aPY723 demonstrates antibody recognition of one band (p165), only in stimulated cells (Figure 1a , lanes 5 and 6; Figure  1b , lanes 3 and 4). Furthermore, the commercial CSF-1R antibody (anti-fms) detects a single band (p165) in aPY723 immunoprecipitates from lysates of stimulated pZen cells (Figure 1a, lane 7) . The very weak p165 band visible in aPY723 immunoprecipitates from unstimulated cells ( Figure 1a , lane 8) is readily explained by autocrine stimulation of CSF-1R by small amounts of CSF-1 produced by this cell line (Tapley et al., 1990) . Such a low level of activated CSF-1R is not detectable in the whole cell lysates ( Figure 1a , lanes 4 and 6). The same precipitates immunoblotted with anti-phosphotyrosine reveal a p165 band only in stimulated cells ( Figure 1a , lanes 9 and 10).
Blocking studies
As shown in Figure 2 , the reactivity of aPY723 could not be blocked by preincubation of the antibody with 100 mM phosphotyrosine alone, 250 mM unphosphorylated peptide 723 (pep723) or 25 mM of an irrelevant tyrosine phosphorylated peptide (in this case derived from animo acids 802 to 816 of the CSF-1R sequence with phosphotyrosine at position 809). However, aPY723 was completely blocked by 1 mM of the phosphopeptide (PYpep723) against which the antibody was raised.
Crossreactivity
Given the known homologies of the intracellular domains of receptor tyrosine kinases, it was necessary to determine whether our anity-puri®ed antibody preparation was speci®c for CSF-1R, or whether it would also recognize other closely-related receptor tyrosine kinases such as KIT and PDGF-R as well as more distantly related receptors such as MET, EGF-R (epidermal growth factor receptor) or p185 neu/ErbB-2 (the product of the neu/ErbB-2/HER-2 gene). To test for crossreactivity to KIT and MET normal human melanocytes were stimulated respectively with MGF (Mast/Stem cell growth factor) or HGF/SF (hepatocyte growth factor/Scatter Factor). Figure 3 shows a set of Western immunoblots of whole cell lysates from unstimulated and MGF-stimulated cells. When probed with anti-KIT antibody the glycosylated (p145) and unglycosylated (p125) forms of the receptor are apparent. Activated, tyrosine phosphorylated KIT is identi®able on the anti-phosphotyrosine blot as a band of 145 kD only in lysates from stimulated cells, however no reactivity was seen with aPY723. The same result was obtained for MET in lysates from HGF/SF stimulated melanocytes, as well as for EGF-R and p185
neu/ErbB-2 in lysates from EGF-stimulated SKBR3 cells and PDGF-Rb in lysates from PDGF-BB stimulated NIH3T3 ®broblasts, which express high levels of the b-isoform of PDGF-R (data not shown). None of the phosphorylated receptor tyrosine kinases tested were detected by aPY723.
Immunocytochemistry and Immunohistochemistry
In order to determine whether our antibody preparation could detect activated, phosphorylated CSF-1R in Western blots of cell lysates were prepared from unstimulated (7) or MGF stimulated (+) normal human melanocytes. The membranes were probed with anti-phosphotyrosine (aPY, lanes 1 and 2), aPY723 (lanes 3 and 4) and anti-KIT (aKIT, lanes 5 and 6). Arrow designates band corresponding to mature form of KIT (145 kDa) Figure 4 Immunocytochemistry and immunohistochemistry using aPY723. CSF-1 stimulated pZen monolayers were doubly stained with antibodies aPY (a) and aPY723 (b) using rhodamine and¯uorescein tags respectively and with DAPI (c). Immunoperoxidase staining with aPY723 of mock treated pZen (d) and BAC1.2F5 cells (e) and CSF-1 stimulated pZen (g) and BAC1.2F5 cells (h). As a control for the staining process and to show the antibody could be blocked by the phosphorylated peptide against which it was raised, a CSF-1R positive/aPY723 positive case was stained with aPY723 (f) and aPY723+10 mM PYpep723 (i). j, k, m (aPY723) and n (anti-CSF-1R) show three areas of a second aPY723 positive case which included both invasive tumor (INV) and intraductal components (CIS, carcinoma in situ), benign tissue (BEN) and macrophages (M). Panels l (aPY723) and o (anti-CSF-1R) show a third case which was CSF-1R positive but aPY723 negative. a±c, e and h were photographed at 6006, k and n at 4006, all other panels were 2006 magni®cation ®xed cultured cells and tissue samples and thus be suitable as a reagent for immunohistochemistry (IHC) of clinical samples, CSF-1 stimulated BAC1.2F5 and pZen cells were ®xed and stained with aPY723. To further demonstrate co-localization of phosphotyrosine and aPY723 reactivities we used immunouorescent staining of pZen cells since the predominant phosphotyrosyl protein is CSF-1R as was seen in Figure 1 . Figure 4a depicts anti-phosphotyrosine antibody staining of CSF-1 treated pZen cells showing reactivity with a predominantly membrane protein. The punctate pattern is consistent with association of CSF-1R with coated pits on the cell surface (Manger et al., 1984; Nichols et al., 1985) . Figure 4b shows the virtually identical¯uorescent pattern seen with aPY723.
We then went on to test the reactivity of aPY723 on paran sections of human breast tumor tissue from patients at Yale New Haven Hospital between 1975 and 1994 which were obtained through the Department of Pathology, Yale University School of Medicine. A total of 126 specimens were stained using aPY723 as an immunohistochemical reagent and compared with serial sections stained with commercial anti-CSF-1R antibody. As summarized in Table 1 , of the 126 specimens evaluated, 114 contained invasive carcinoma and 58 contained intraductal carcinoma. Of the cases with invasive tumor, 83 (73%) were positive for CSF-1R and of these, 59 (72%) stained with aPY723 (i.e. approximately 52% of all invasive cases). Cytoplasmic staining of the invasive component was strong (52+ on a scale of 0 ± 4) in 63 of the CSF-1R positive cases and 45 of the aPY723 reactive cases. Focal staining with anti-CSF-1R and aPY723 (scores52) was present in 20 and 15 samples respectively or about 25% of the positive cases for both antibodies. CSF-1R was also expressed strongly in 29 (52%) of the specimens that contained an intraductal component and 22 (38%, or 76% of CSF-1R-positive cases) stained with aPY723. The frequency with which aPY723 stained invasive cancer was not signi®cantly dierent from that for the intraductal component (P=0.304). Although benign cells in 26 of 68 cases containing a benign component were clearly stained with commercial anti-CSF-1R antibody, de®nite staining by aPY723 was observed in only three of these. It should be noted also that staining with both anti-CSF-1R and aPY723 was much stronger overall in invasive tumor cells than in the cases in which benign epithelium stained (P50.05). Since adjacent benign tissue may represent the spectrum of phenotypes that one observes in any neoplastic tissue, which is often a mixture of benign, hyperplastic, dysplastic and neoplastic cell types, it is not surprising that some may express low levels of CSF-1R. Epithelial cells in paran sections of normal breast tissue (samples from reduction mammoplasty) did not stain with either anti-CSF-1R or aPY723 (not shown). Constitutively activated CSF-1R in macrophages was expected to react with aPY723 and distinct staining was found in 32 cases. Figure 4 shows examples of invasive tumor cases stained with aPY723 and commercial anti-CSF-1R.
We further tested the ability of various competing antigens to block the immunoreactivity of aPY723 on serial sections of two positive cases. One case is shown in Figure 4 staining with aPY723 (Figure 4f ) but after pretreating the antibody with 10 mM PYpep723 staining was completely blocked (Figure 4i ), in good agreement with immunoblot results described above (Figure 2) . Neither the unphosphorylated peptide (pep723), a dierent phosphotyrosine peptide (PYpep809) nor phosphotyrosine alone blocked aPY723 staining of additional serial sections (not shown). These results demonstrate that staining is not due to non-speci®c binding.
Discussion
This communication reports that greater than 50% of breast cancers are stained by an immunological reagent capable of discriminating activated, tyrosine phosphorylated CSF-1R from its inactive, unphosphorylated form. This antibody preparation appears to be speci®c for activated CSF-1R in whole cell extracts and in formalin ®xed cells and tissue specimens. Crossreactivity with phosphorylated/activated PDGF-R, KIT, MET, EGF-R and neu/erbB-2/ HER-2 was not detected on Western blots of whole cell lysates.
The phosphorylation of proteins by receptor tyrosine kinases provides one of the major signaling mechanisms for cellular responses to growth factor stimuli and is absolutely essential for normal cell growth and dierentiation. Many of these kinases have been found to be the gene products of cellular protooncogenes which, when altered or overexpressed, lead to uncontrolled proliferation (Cantley et al., 1991) . Antibodies speci®c for phosphotyrosine residues were ®rst prepared by Ross et al. (1981) and later by several b The intensity of cytoplasmic staining was graded on a scale of 0 ± 4 (0= no staining, 4= intense staining). A score of 1 was given if staining was faintly detected.
c Only 56 specimens were stained with anti-CSF-1R. d Colloid carcinoma, 1 (CSF-1R positive); lobular cancer, 2 (one positive for CSF-1R).
e Atypical ductal hyperplasia laboratories using modi®cations of the original method (reviewed in Wang, 1988) . Anti-phosphotyrosine antibodies have since been used extensively to detect and isolate a wide range of tyrosine phosphorylated proteins activated by extracellular signals or by mutations (Wang, 1988; Comoglio et al., 1990; Stern, 1991) . However, the usefulness of such antibodies is limited by the fact that they cannot be used to detect speci®c proteins phosphorylated on tyrosine. The inability to distinguish dierent tyrosine phosphorylated proteins is especially problematic if one is studying phosphorylation in clinical specimens where the ability to detect the phosphorylation status of a speci®c receptor kinase, or other relevant protein, may be helpful in predicting the outcome of the disease. Another approach has been to raise conformationsensitive antibodies which recognize a conformational change in a speci®c domain that occurs after phosphorylation (Bishayee et al., 1988; Keating et al., 1988; Downing et al., 1991; Panneerselvam et al., 1995) . However, such antibodies may not be able to discriminate between the active and inactive forms of a protein in histologic specimens that have been subjected to denaturation as a result of ®xation methods.
Recently, phosphorylation-sensitive antibodies have been prepared which recognize speci®c proteins only when they have been phosphorylated on the speci®c residue incorporated in the phosphopeptide to which the antibody was raised. These antibodies have been successfully employed to detect dierentially phosphorylated proteins in cell lysates and clinical specimens (Bangalore et al., 1992; Epstein et al., 1992; DiGiovanna and Stern, 1995; Bacus et al., 1996) . The success of this recent technique has prompted us to apply a similar approach to evaluate CSF-1R phosphorylation in breast carcinomas.
In order to prepare our phosphospeci®c CSF-1R Tyr723 antibody (aPY723), we had a speci®c phosphopeptide (pep723) synthesized to match CSF-1R amino acid residues 716 ± 730 including a phosphotyrosine in place of tyrosine at position 723. Tyr723 is present in the tyrosine kinase insert domain of CSF-1R, a region with low homology to the amino acid sequence of kinase inserts in other related growth factor receptors (Yarden et al., 1986) . One of at least four major autophosphorylation sites in human CSF-1R, Tyr723 has been reported to couple CSF-1R with signal transduction pathways through activation of PI3 kinase (Reedijk et al., 1990 (Reedijk et al., , 1992 which has been implicated in the activation of protein kinase C and p70 S6 kinase, members of the serine/threonine kinase family (Weng et al., 1995; Akimoto et al., 1996) . The ability of CSF-1 to stimulate the growth rate of Rat2 ®broblasts expressing murine CSF-1R mutated at Tyr721 is signi®cantly impaired compared to cells expressing wild type receptor (van der Geer and Hunter, 1993) . We have also found that Tyr721 is necessary for in vitro anchorage-independent growth and in vivo metastatic ability of mammary epithelial cells engineered to overexpress CSF-1R (Sapi et al., 1996) .
To test for crossreactivity, we selected the most probable homologous proteins, compared pep723 to their amino acid sequences by computer analysis and found varying degrees of homology to short, phosphotyrosine-containing sequences from PDGFRb, KIT and MET, speci®cally at sites containing the YXXM motif which is the concensus binding site for the PI3 kinase p85 subunit (Cantley et al., 1991) . No matches were found to FGF-R, EGF-R or neu/ erbB-2/HER-2. Of the receptors that were checked, none were crossreactive with aPY723. While it is tempting to speculate that aPY723 is recognizing a very short peptide motif including the phosphotyrosine and immediate¯anking residues it is also possible that the secondary structure of the peptide sequence plays a signi®cant role in antibody recognition. Therefore peptide sequence alone cannot be used to predict crossreactivity of aPY723 to other proteins that may be phosphorylated and we cannot rule out the possibility that some cells may have an unanticipated peptide having a phosphotyrosyl site with sucient similarity to crossreact with aPY723. Our attempts to prepare antibodies speci®c for another site of tyrosine phosphorylation, Tyr809, were less successful in that they yielded a reagent capable of recognizing not only ligand activated CSF-1R but also PDGF-R, KIT, MET, EGF-R and neu/erbB-2/HER-2 (unpublished observations).
In the present study, the high percentage of receptor positive cases is in good agreement with previous IHC studies in which 58% of all breast carcinomas expressed CSF-1R (Scholl et al., 1994) and at least 85% of invasive breast carcinomas expressed CSF-1R (Kacinski et al., 1991; Tang et al., 1992) ; and with studies showing elevated levels of CSF-1R mRNA in the majority of cases of breast cancer tested by in situ hybridization (Kacinski et al., 1991) . However, the mere presence of receptor may not represent a complete picture of the dynamics of autocrine/ paracrine stimulation. In ovarian carcinoma patients, elevated circulating levels of CSF-1 have been shown to correlate with advanced disease and poor outcome (Kacinski et al., 1989a,b) and high levels of CSF-1 have also been found in the sera of patients with lung and endometrial carcinomas (Kacinski et al., 1990b; Baiocchi et al., 1991) . Coexpression of CSF-1/CSF-1R has been found by immunohistochemical techniques in 30 ± 36% of breast cancer patients and correlates with an adverse prognosis (Kacinski et al., 1991; Scholl et al., 1994) . Lower et al. (1993) , using both an in vitro assay for tyrosine protein kinase (TPK) activity from fresh tissue samples and IHC with an anti-phosphotyrosine antibody, found signi®cantly more TPK activity and tyrosine phosphorylation in breast cancer specimens than in normal breast tissues. Furthermore, TPK activity was greater in in®ltrating ductal cancers than in the less aggressive intraductal disease. Although it is possible that a signi®cant portion of the activity and phosphorylation they were observing was due to activated CSF-1R, they were unable to identify which cellular proteins were responsible for the observed results. The preparation of aPY723 has enabled us to study speci®cally the activation/phosphorylation of CSF-1R in vivo in breast carcinoma.
As an immunological reagent capable of distinguishing phosphorylated CSF-1R from the inactive, unphosphorylated form, aPY723 stained 52% of a moderately large sample group of malignant breast cancers in our study. This represents the ®rst direct evidence of in vivo phosphorylation of expressed CSF-1R in clinical specimens of mammary carcinoma. It is possible that IHC studies using a aPY723 may be a better in vivo measure of the level of autocrine/ paracrine activation of CSF-1R and of the Tyr723 modulated signal transduction pathway. We now have preliminary immunohistochemical data using aPY723 on patient specimens demonstrating a statistically signi®cant (P50.01) correlation between the phosphorylation state of PY723 in CSF-1R of breast carcinoma epithelial cells and the metastasis-free survival of nodenegative breast cancer patients (unpublished data). More comprehensive large scale studies aimed at de®ning the role that expression of activated CSF-1R plays in mammary, endometrial and ovarian carcinoma are currently underway and should help us de®ne the relationship of speci®c CSF-1R signal transduction pathways to such clinical parameters as time to local relapse, distant metastasis or length of patient survival.
Materials and methods
Cells and growth factor stimulation
The pZen cell line which are BALB/c 3T3 ®broblasts retrovirally transformed to constitutively express high levels of murine CSF-1R at the cell surface, was obtained from L Rohrschneider . BAC1.2F5, an SV40-immortalized murine macrophage line, was obtained from ER Stanley (Morgan et al., 1987) . SKBR3, a human breast carcinoma derived cell line expressing EGF-R and p185 neu/ErbB-2 (DiGiovanna and Stern, 1995) and NIH3T3 (immortalized murine ®broblast cell line) were obtained from the American Type Culture Collection. Normal human melanocytes, which express KIT and MET, were cultured from neonatal foreskins as previously described and modi®ed in BoÈ hm et al., 1995) . All cells were maintained at 378C and 5% CO 2 . NIH3T3 and pZen were grown in Dulbecco's modi®ed Eagle's/Ham's F-12 medium (DME/F-12, 1 : 1 mixture, Sigma) with 10% calf serum (GIBCO). To induce phosphorylation of CSF1-R, pZen cells were treated with 250 ng/ml recombinant human CSF-1 (rhCSF-1, 6.03610 77 units/mg as determined by a NSF60 bioassay, Chiron Corp.) in serum-free DME/F-12 medium for 2.5 ± 3 min at 258C. To stimulate phosphorylation of PDGF-Rb, NIH3T3 cells were treated for 6 min at 378C with 10 ng/ml human recombinant platelet derived growth factor BB (PDGF-BB, Sigma) in serum-free DME/F-12. BAC1.2F5 cells were grown in Iskove's medium (Sigma) supplemented with 10% fetal bovine serum and 100 ng/ml rhCSF-1. SKBR3 cells were grown in McCoy's 5A (Sigma) with 15% fetal bovine serum (GIBCO). Prior to stimulation, near con¯uent SKBR3 were starved overnight in serum-free DME/F-12 and stimulated with 100 ng/ml epidermal growth factor (EGF, Sigma) in serum-free DME/F-12 for 10 min at room temperature. Normal melanocytes were stimulated for 15 min at 378C with 100 ng/ml Mast/Stem cell growth factor (MGF, Immunex) or 40 ng/ml hepatocyte growth factor/Scatter Factor (HGF/SF, Genentech) as previously described (BoÈ hm et al., 1995) . For immunocytochemistry, BAC1.2F5 cells and pZen cells were cultured using Lab-Tek 1 Chamber Slides 2 (Nalge Nunc International). Cells were seeded at 70 ± 80% con¯uence and cultured overnight.
Peptide synthesis
Synthetic, nonphosphorylated peptides were prepared at the WM Keck Facility at Yale University using solid phase, tBOC (N-tert-Butyloxycarbonyl)-chemistry. Amino acids were coupled by activated esters and ®nal deprotection/cleavage was done using hydrogen¯uoride. Crude synthetic phosphorylated-peptides were synthesized at the University of Michigan Protein and Carbohydrate Structure Facility using FMOC (N-9-fluorenylmethyloxycarbonyl)-chemistry in which phosphorylated tyrosine residues were incorporated as Fmoc-tyrosine phosphate with no side arm protecting group. Puri®cations of all peptides were performed at the Keck Facility using Vydac C18 reversed-phase columns and a linear gradient from 0.05% TFA (tri¯uoroacetic acid) to 80% acetonitrile/0.05% TFA. Final products were lyophilized and characterized by analytical RP-HPLC, amino acid analysis and laser desorption mass spectrometry. Peptide 723 (pep723) and phosphopeptide 723 (PYpep723) correspond to amino acids 716 to 730 of human CSF-1R, SSQGVDT(Y/ pY)VEMRPVS, which are located in the kinase insert domain (Coussens et al., 1986) . PYpep809 corresponds to amino acids 802 ± 816, DIMNDSNpYIVKGNAR, located in the second part of the kinase domain (Coussens et al., 1986) . Used here as an irrelevant, phosphorylated peptide control for antibody blocking, it includes phosphorylated tyrosine 809 and is only 36% similar to PYpep723.
Anti-phosphopeptide antibody production and puri®cation
The phosphorylated peptide PYpep723 was coupled to bovine serum albumin (BSA) with glutaraldehyde and injected into New Zealand rabbits as previously described (Marcussen and Poulsen, 1991; Bangalore et al., 1992) . Serum samples were screened weekly for ability to detect CSF-1R on Western blots of CSF-1 stimulated pZen cell lysates compared to standard detection by anti-CSF-1R antibody (anti-fms, Upstate Biotechnology Inc. # 06-175), a human crossreactive, anity puri®ed polyclonal antibody against the cytoplasmic domain of mouse CSF-1R. Antiserum collected from exsanguination was anitypuri®ed as previously described (Bangalore et al., 1992) , which includes consecutively cycling the rabbit serum multiple times through the following three columns: BSAagarose, phosphotyrosine coupled to A-Gel 10 and nonphosphorylated peptide coupled to A-Gel 10. The ®nal ow-through was then passed three times through a column of phosphopeptide coupled to A-Gel 10 and the bound antibodies eluted, dialyzed and concentrated. The resulting anity puri®ed antiserum is designated aPY723.
Other antibodies
We used anti-phosphotyrosine (mAb clone 4G10) and anti-EGF-R (# 06-129) (Upstate Biotechnology Inc, UBI), antic-ErbB-2 (pAb-1, Triton Diagnostics), anti-PDGF-Rb (C3a) from Lisa Petti (Nilson and DiMaio, 1993) , peroxidase-labeled anti-mouse IgG (Amersham Life Science), peroxidase-labeled anti-rabbit IgG (ICN), normal goat serum and biotin-labeled goat anti-rabbit IgG and rhodamine-conjugated anti-mouse IgG (Vector). Antibodies to KIT and MET were as described previously Halaban et al., 1992) .
Lysate preparation, immunoprecipitation, PAGE and Western immunoblot analysis
Cells were washed twice with ice cold phosphate buered saline (PBS; 137 mM NaCl, 2.75 mM KCl, 10 mM Na 2 HPO 4 , 1.75 mM KH 2 PO 4 , pH 7.4) plus 0.5 mM sodium orthovanadate and kept on ice throughout lysate preparation. NIH3T3, pZen and SKBR3 cells were lysed in RIPA buer (10 mM sodium phosphate buer, pH 7.0, 150 mM NaCl, 1 mM EDTA, 1% deoxycholate, 1% Triton X-100, 0.1% SDS, plus freshly added 22 mg/ml aprotinin and 1 mM sodium orthovanadate) as previously described (Stern, 1991; DiGiovanna and Stern, 1995) . Protein concentration was determined using BioRad protein assay reagent (BioRad). BAC1.2F5 and melanocyte lysates were prepared directly in hot SDS-sample buer . For immunoprecipitation, 2.5 mg of aPY723 was mixed with 0.5 mg protein and 50 ml packed, washed protein-A-agarose beads (UBI) and rocked at 48C for 2 h. The beads were washed once with lysis buer, once with PBS plus 0.5 mM sodium orthovanadate and the antibody-antigen complexes were eluted with 26 sample buer (1008C for 5 min). Whole cell lysates and immunoprecipitates were separated in 7.5% or 10% polyacrylamide minigels and transferred to polyvinylidenē uoride (PVDF) membrane (Immobilon P, Millipore Corp.).
The membranes were blocked overnight at 48C then incubated 2 h at 258C with primary antibody in 10% nonfat milk in PBS plus 0.5% Tween20 (aPY723 and anti-fms) or 5% BSA in 0.1 M NaCl, 10 mM Tris-HCl, pH 7.5 plus 0.1% Tween20. aPY723 was used at 1 : 7500 and all other antibodies were diluted as recommended by the supplier. After washing and incubation with appropriate secondary antibody linked to horseradish peroxidase, the antigenantibody complexes were detected by enhanced chemiluminescence (SuperSignal 2 , Pierce) according to the manufacturer's protocol. For serial immunoblotting, blots were stripped in 2% (w/v) SDS, 62.5 mM Tris-HCl, pH 6.8, 100 mM b-mercaptoethanol at 708C for 30 min and washed twice in 150 mM NaCl, 10 mM Tris-HCl, pH 7.4 prior to each subsequent antibody probe. Antibody blocking studies were performed by ®rst diluting aPY723 to 0.05 mg/ml in PBS. Diluted antiserum was mixed with an equal volume of blocking agent (®nal concentrations are given in the legend to Figure 2 ) and left at 48C for 15 min. Antiserum/blocking agent mixtures were then diluted into the 10% milk solution giving a ®nal aPY723 dilution of 1 : 7500, and used for immunoblotting as described above.
Immunocytochemistry and immunohistochemistry
Fluorescence immunocytochemistry was performed on BAC1.2F5 cell monolayers grown on chamber slides as described above. Cells were washed with cold PBS four times and ®xed in 10% buered formalin (Sigma) for 10 min at 258C followed by a series of washes in graded alcohol, a PBS rinse, Saponin (0.05%) for 30 min at 258C and extensive rinses in PBS. Slides were blocked at least 20 min in PBS plus 1% BSA with 1 : 200 dilution of normal goat serum. Primary antibodies (aPY723 and antiphosphotyrosine-4G10) were diluted in PBS plus BSA, applied to the slides and left overnight at 48C. After extensive washing with PBS, slides were exposed to 1 : 200 dilution of the biotinylated secondary antibody (antirabbit) for 1 hr at 258C, extensively washed again in PBS, exposed to Fluorescein Avidin DCS (Cell sorting grade, Vector) and rhodamine-conjugated secondary antibody (anti-mouse, Vector) for 30 min each at 258C according to supplier's protocol and again extensively washed with PBS. After a ®nal staining with DAPI (Sigma) slides were mounted with aqueous mounting medium plus DABCO antifade (Sigma).
Immunoperoxidase based cytochemistry and histochemistry was performed using anti-CSF-1R (UBI # 06-175) at a 1 : 200 dilution and aPY723 at 1 : 50. All antibodies were diluted in PBS plus 1% BSA. A total of 126 surgical breast specimens were ®xed in 10% neutral buered formalin and paran embedded by standard procedure. Four or ®ve micron sections were deparanized and rehydrated through graded alcohols. BAC1.2F5 and pZen cells were grown on chamber slides as described above. Endogenous peroxidase activity was quenched using 2% hydrogen peroxide in methanol for 30 min at room temperature. The cells and tissues were rehydrated through graded alcohols, washed with PBS for 10 min, incubated with diluted goat serum (1 : 200) for 20 min at room temperature, followed by incubation with primary antibody overnight at 48C in a humidi®ed chamber. Slides were then rinsed with 1% Triton-PBS, washed with PBS for 10 min, incubated with biotin-conjugated goat antirabbit IgG (1 : 250) for 30 min at room temperature and rinsed again in PBS for 10 min. Immunoperoxidase staining was carried out using the Vectastain ABC Elite and DAB peroxidase substrate kits (Vector) following the manufacturer's protocol. Slides were counterstained with Harris haematoxilin solution (Sigma).
Immunostained sections were evaluated by two pathologists (PLP and DC). The intensity of cytoplasmic staining was graded on a scale of 0 ± 4 (0=no staining, 4=intense staining). The distribution of staining by anti-CSF-1R and aPY723 was individually graded in the invasive carcinoma component, the intraductal carcinoma and the benign breast tissue. The reactivity of both antibodies in macrophages was noted when present. Staining was considered focal when only few cells were immunoreactive. Dierences in the staining of individual components by anti-CSF-1R and aPY723 were evaluated by the Wilcoxon Signed Ranks test. P-values less than 0.05 were considered statistically signi®cant.
